Drugs / HNC364
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06798519 | May → Dec 2026 expected | Parkinson disease | Guangzhou Henovcom Bioscience Co. Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05523570 | Aug 2022 → Apr 2024 | Parkinson disease | Guangzhou Henovcom Bioscience Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HNC364 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06798519 ↗ |
| Route | Intramuscular | “receive 20 mg HNC364 intramuscular administration” NCT05523570 ↗ |